

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 August 2024 (15.08.2024)



(10) International Publication Number
WO 2024/167814 A1

(51) International Patent Classification:

C12N 15/62 (2006.01) C12N 15/90 (2006.01)
C12N 5/074 (2010.01) C12N 9/02 (2006.01)

(21) International Application Number:

PCT/US2024/014395

(22) International Filing Date:

05 February 2024 (05.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/443,614 06 February 2023 (06.02.2023) US
63/503,640 22 May 2023 (22.05.2023) US

(71) Applicant: **BLUEROCK THERAPEUTICS LP**
[US/US]; 238 Main Street, 3rd Floor, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **MCAULIFFE, Conor**; c/o BlueRock Therapeutics LP, 238 Main Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). **SOH, Chew-Li**; c/o BlueRock Therapeutics LP, 238 Main Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). **TOMISHIMA, Mark**; c/o BlueRock

Therapeutics LP, 238 Main Street, 3rd Floor, Cambridge, Massachusetts 02142 (US).

(74) Agent: **ABU-SHAAR, Muna** et al.; Biospark Intellectual Property Law, 1 Broadway, 14th Floor, Cambridge, Massachusetts 02142 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: DEGRON FUSION PROTEINS AND METHODS OF PRODUCTION AND USE THEREOF




FIG. 1A




FIG. 1B



FIG. 1C




FIG. 1D

(57) Abstract: The present disclosure relates in part to degron-based methods for controlling gene-edited therapeutic cells administered to patients, and targeting constructs encoding degrons, which are suitable for generating gene-edited target cells that can be eliminated following administration to a patient.

[Continued on next page]

WO 2024/167814 A1

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*